INTRODUCTION
Additionally, it also induces expression of plasminogen activators and metalloproteinases; thereby, promoting a prodegradative environment, facilitating cellular migration and invasion [9] . Downstream signaling upon activation of VEGFRs has also been associated with inhibition of apoptosis and decreased production of nitric oxide [10] . Thus, the VHL-HIF pathway is pivotal to the pathobiology of RCC, and has been crucial in the development of targeted agents that include VEGFR inhibitors as well as antibodies to circulating VEGF. playing a significant role in angiogenesis [11] .
This has expanded available molecular targets and led to the development of mTOR inhibitors, temsirolimus and everolimus, which have demonstrated efficacy in mRCC [12, 13] .
Since its Food and Drug Administration (FDA) approval in January 2012, the receptor selectivity, potency, high objective response rate (ORR), and tolerability of axitinib have generated considerable interest. The clinical evidence supporting the current role of axitinib in the management of mRCC is reviewed in this article, with a special emphasis on its place in current treatment regimens. In addition, management of drug toxicities and ongoing investigational trials centered on axitinib are detailed.
METHODS
A PubMed search was conducted using the key terms "axitinib" and "renal cell cancer." Additionally, proceedings from major congresses in North America and Europe over the last 5 years were reviewed for abstracts related to axitinib in RCC.
MECHANISM OF ACTION
Axitinib is a second-generation, indazolederived molecule that inhibits VEGFR-1, 2, and 3 at therapeutic plasma concentrations; thereby, blocking VEGF-mediated angiogenesis, cellular adhesion, migration, and eventually resulting in cellular apoptosis. Axitinib binds selectively to the adenosine triphosphate (ATP)-binding intracellular domain of VEGFR-1, 2, and 3 at nanomolar concentrations, stabilizing an inactive confirmation of these kinases and, thus, inhibiting downstream signal transduction [14, 15] . In fact, the half maximal inhibitory concentration (IC50) of axitinib for VEGFR-1, 2, and 3 inhibition is 0.1, 0.2, and 0.1-0.3 nM, respectively, distinguishing it as the most potent VEGFR-1 inhibitor for the treatment of mRCC [16] . Despite platelet-derived growth factor receptor and C-Kit inhibitory effects observed in vitro, axitinib's potency against non-VEGF receptors is about eight-times weaker and, at clinically achieved plasma levels, VEGF inhibition alone is believed to be responsible for the observed clinical benefits [10] . This selectivity is likely responsible for the potent "on-target" effect and toxicity profile of this agent.
CLINICAL DATA
In the first phase 1 study of axitinib, 36 patients with advanced solid malignancies were treated with axitinib with total daily dose varying from 10-60 mg [17] . This trial helped define the maximal tolerated dose of axitinib as 5 mg orally twice a day (b.i.d.). Important dose-limiting toxicities included hypertension, diarrhea, and stomatitis. The incidence and severity of hypertension were proportional to drug dosage.
Linear pharmacokinetics were observed in the dose range evaluated in this trial. Subsequent phase 1 studies conducted among Japanese and Chinese patients have confirmed similar pharmacokinetics and the adverse-effect profile of axitinib in non-Caucasian subjects [18, 19] .
Another phase 1 study of axitinib in 12 Japanese patients confirmed the tolerability and efficacy of this dose, and demonstrated a significant correlation between axitinib exposure and decline in soluble VEGFR-2 levels [20] .
Three independent phase 2 trials subsequently evaluated the role of axitinib in mRCC patients refractory to prior therapy ( [24] . Also, this longer follow-up did not reveal any new toxicity in the patient cohort [24] . Narrower distribution of peak drug concentration on day 1 of cycle 1, higher ORR, and better baseline performance status were characteristics significantly associated with 5-year survival.
Subsequently, a second phase 2 study of 62 patients was conducted to evaluate response to axitinib in patients who had received prior VEGF therapy with sorafenib [22] . In this A phase 2 study of axitinib in Japanese patients who were cytokine refractory has also yielded similar results, with an ORR of 50.0%, and median PFS of 11.0 months, which confirms the previously observed efficacy and tolerability in non-Caucasian populations [23] .
Phase 3 AXIS Study
The AXIS trial was a pivotal, phase 3, randomized controlled study of 723 patients, which 
PHARMACODYNAMICS AND PHARMACOKINETICS
Available as 5 mg and 1 mg tablets, axitinib achieves peak plasma concentration in 3 hours after a high-fat, high-calorie meal, and 2 hours after overnight fasting [31] . According to may decrease plasma concentrations [32] .
Pharmacodynamic Variability
Investigators recently analyzed single nucleotide polymorphisms (SNPs) in VEGF and related receptors, and their correlation with hypertension and PFS in the phase 3 axitinib AXIS study [35] . Preliminary data suggest that three VEGF-A SNPs revealed potential association between VEGF genotype and PFS. Although these data are preliminary, it is noteworthy that these polymorphisms were not associated with axitinib-related hypertension or diastolic hypertension [35] . Additionally, a meta-analysis of pooled data from 11 axitinib studies has not revealed a significant association linking gene polymorphism for enzymes CYP3A4/5, CYP1A2, CYP2C19, UGT1A1, and P-gp to variations in axitinib pharmacokinetics [36] . Additional investigation into pharmacogenomics as they relate to axitinib efficacy and toxicity is needed.
DOSE ESCALATION
In Less common side effects included bleeding, thromboembolism, and proteinuria. Table 2 [25] summarizes the various grades of toxicities observed in the phase 3 study. The decreased incidence of myelosuppression, hand-foot syndrome (palmar-plantar erythrodysesthesia), [41, 42] . 
TOXICITIES AND THEIR MANAGEMENT

Hypertension as a Biomarker
Hypertension is a significant adverse effect of 
